North America Novel Drug Delivery Systems (NDDS) Market Trends
Oral Drug Delivery Systems is Expected to Grow Fastest during the Forecast Period
Oral drug delivery has found to be the most preferred and convenient route of drug administration, due to high patient compliance, cost-effectiveness, least sterility constraints, flexibility in the design of dosage form, and ease of production. In oral administration, drugs should be protected under unstable biological environments, including drug degradation induced by the GI tract and first-pass liver effects after oral administration before reaching the targeted sites. The oral drug delivery is majorly driven by the increasing incidence of chronic diseases, reformulation and repositioning of drugs using advanced oral delivery systems, and huge investments made by big pharmaceutical companies on in-house capabilities for the development of oral drug delivery technologies. According to Globocan, 2018 there were a total of 2,129,118 incident cancers in the United States for the year 2018.North America Novel Drug Delivery Systems (NDDS) Industry Overview
The market players are focusing on the development of innovative treatment options in order to grab maximum market share. Some of the market players are Abbott Laboratories, AstraZeneca PLC, Bayer AG, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Sanofi SAAdditional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- AstraZeneca PLC
- Bayer Healthcare Pharmaceuticals
- GlaxoSmithKline PLC
- Johnson & Johnson
- Novartis AG
- Merck & Co.
- Sanofi SA
- Roche Holding AG
- Pfizer Inc.
Methodology
LOADING...